UPC
NASDAQ · Pharmaceuticals
Universe Pharmaceuticals Inc
$6.05
-0.11 (-1.79%)
Financial Highlights (FY 2026)
Revenue
180.31M
Net Income
-37,075,055
Gross Margin
35.3%
Profit Margin
-20.6%
Rev Growth
-28.1%
D/E Ratio
0.16
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 35.3% | 35.3% | 38.4% | 38.4% |
| Operating Margin | -19.0% | -17.1% | 14.7% | 13.8% |
| Profit Margin | -20.6% | -19.5% | 13.5% | 15.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 180.31M | 250.67M | 677.4K | 654.6K |
| Gross Profit | 63.61M | 88.44M | 259.9K | 251.1K |
| Operating Income | -34,294,967 | -42,910,427 | 99.6K | 90.3K |
| Net Income | -37,075,055 | -46,388,919 | 91.7K | 101.2K |
| Gross Margin | 35.3% | 35.3% | 38.4% | 38.4% |
| Operating Margin | -19.0% | -17.1% | 14.7% | 13.8% |
| Profit Margin | -20.6% | -19.5% | 13.5% | 15.5% |
| Rev Growth | -28.1% | -28.1% | +6.4% | -8.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.97M | 1.97M | 155.8K | 159.5K |
| Total Equity | 11.95M | 11.95M | 1.13M | 1.17M |
| D/E Ratio | 0.16 | 0.16 | 0.14 | 0.14 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -30,045,841 | -39,682,398 | 139.8K | 143.9K |
| Free Cash Flow | — | — | 93.2K | 84.6K |